Close menu




April 21st, 2022 | 13:58 CEST

Bayer AG, Perimeter Medical, Twitter - Shareholder interests drive share price performance

  • medtech
  • Technology
Photo credits: pixabay.com

The life science and medical technology sectors offer investment opportunities. Whether with old hands like Bayer AG or up-and-coming innovative startups like Perimeter Medical, each company has its own fascination. Strong corporate management that acts in the interests of shareholders provides additional confidence. The latter, in particular, is currently being put to the test at the short messaging service Twitter. Elon Musk's takeover bid threatens to dilute existing investors' shares with a poison pill.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: BAYER AG NA O.N. | DE000BAY0017 , PERIMETER MED.IMAG.AI | CA71385D1078 , TWITTER INC. DL-_000005 | US90184L1026

Table of contents:


    Bayer AG - Cap on Executive Board salary

    Singapore-based investor Temasek has been financing Bayer Group since 2016 when Bayer acquired US-based Monsanto under the care of CEO Werner Baumann. Along with the responsibility for the consequences of the deal, including lawsuits for damages in the billions based on the suspicion that the active ingredient glyphosate could cause cancer in humans.

    Temasek argues that the share has lost 48% of its value since its investment. At the upcoming shareholder meeting, they are therefore likely to call for a vote of no confidence in the CEO or a vote against approving the actions of Bayer's management.

    On the other hand, two well-known stockholder advisors stand by the current company CEO. In their latest reports, the two leading stockholder advisors, ISS and Glass Lewis, reiterate their support for discharging the Group's management at the upcoming annual stockholders' meeting.

    "We are concerned about two decisions made by the board in the last fiscal year, namely the exclusion of the impact of litigation from the free cash flow metric under the annual bonus program and the full bonuses for a departing board member," Glass Lewis told Bloomberg.

    Things will get exciting at the Annual Stockholders' Meeting on April 29, 22. According to Wallmine, Baumann earns EUR 5.7 million per year as Chairman of the Board of Management and Chief Executive Officer of Bayer AG. A more detailed analysis of the Bayer group can be found here.

    Perimeter Medical - Innovative precision medicine in the fight against cancer

    Through various corporate acquisitions, the Bayer Group also has a foot in the medical technology sector of imaging diagnostics. For example, the Group supplies contrast materials administered to patients before each visit to the MRI tube. The medical imaging division has been one of the first to catch the eye of investors in recent years, thanks to innovative AI technologies.

    Perimeter Medical (PINK) is one such company that is setting out to gently change the way cancer patients are treated. Until now, surgeons have had to wait for tissue sample analyses from the lab before removing a malignant tumor from a patient. That results in a threatening loss of time, and there is also no guarantee that the cancer will be prevented from spreading after surgery. With Perimeter Medical Imaging, surgeons have immediate, valuable, real-time tissue information that helps them perform customized surgery on the patient in the field.

    Thanks to the tireless work of CEO Jeremy Sobotta, affected patients can receive more precise care through new examination and treatment methods. Sobotta is a seasoned expert in his industry. He worked as a controller in the orthopedics division of Smith and Nephew. At Stryker, he has held positions of increasing responsibility, including head of finance for the surgical business unit. His specialty is medical device commercialization.

    The Canadian/US MedTech startup will be one of 60 companies appearing at the prestigious Bloom Burton & Co trade show in Toronto, Canada, on May 2-3. The webcast of Perimeter Medical's presentation is available here.

    Twitter - Poison pill for shareholders

    Elon Musk last week offered to buy messaging services platform Twitter for the equivalent of EUR 38.6 billion. He offered EUR 50.01 (USD 54.20) per share, a 38% premium to Twitter's closing share price on April 1. To Twitter Chairman Brett Taylor (Co-Founder Salesforce), Musk said, "My offer is my best and final offer. If it is not accepted, I will have to reconsider my position as a shareholder." Musk had acquired just under 9% of the shares and cornered the board with his new takeover bid. By law, if Twitter rejects the offer, they are not acting in the best interests of shareholders.

    And there came the poison pill for investors. A poison pill is a nickname for a procedure that allows shareholders to buy more shares of a company at a discount, diluting the value of each share. Twitter's justification for the practice is to "protect shareholders from coercive or otherwise unfair takeover tactics." The poison pill would give shareholders much more voting power, while Elon Musk's shares would be severely diluted.

    But it seems that Twitter did the math without the Tesla and SpaceX CEO's fanbase. The man who has already caused the crypto market to fluctuate wildly in price is playing cat and mouse with his 82 million Twitter followers. To put that in perspective, that is roughly the number of citizens living in Germany that follow him. Musk is hinting that he is making shareholders an offer they will not refuse - loosely based on "The Godfather." "Love me tender" or "____ is the night" (spoiler: Tender is the night) he teases his audience. It will be interesting to see in which direction the Twitter share price will soon move.


    A board of directors should stand up for the interest of its shareholders and communicate what challenges a company will face in the coming months. In the opinion of two leading stockholder advisors, this should also be reflected in one's salary. Since the Monsanto acquisition, Bayer's share price has fallen 48%, much to the frustration of Singapore-based investor Temasek. Perimeter Medical Imaging, on the other hand, is doing more innovatively and with a more upbeat sentiment. A small and fast-growing MedTech company that supports treating physicians in their medical decision-making with a real-time diagnostic solution for the benefit of patients. Sharing in the success there makes one want to know more. Twitter shareholders, meanwhile, can get out the popcorn and watch the US giants battle it out. At stake is nothing less than freedom of expression, which may no longer be as free as some think on the platform due to Twitter's jaded management.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by Nico Popp on September 27th, 2022 | 10:50 CEST

    Plug Power, dynaCERT, Varta: Where there is shadow, there is also light

    • Hydrogen
    • GreenTech
    • Technology

    GreenTech shares have been booming in recent weeks, and rightly so: regenerative energy sources and innovative drives are now often even cheaper than proven technology. Coupled with zero emissions, this is a decisive advantage. We explain why some shares are nevertheless weakening and show where there are interesting opportunities.

    Read

    Commented by André Will-Laudien on September 26th, 2022 | 11:36 CEST

    Favorable entries at Kion, Defense Metals, Nordex: The GreenTech rally is coming back soon!

    • Mining
    • RareEarths
    • GreenTech
    • Technology

    The daily analysis of stock market movements may not be an absolute joy for many investors at the moment. Nevertheless, in addition to numerous burdens, there are also bright spots. The warehouse logistics expert Kion is a long-term growth stock available now at 80% below its high. At rare earth explorer Defense Metals, initial drilling is delivering good results. GreenTech stocks JinkoSolar and Nordex should benefit from the boom in alternative energy generation for many years to come. As the saying goes, "Buy when the guns are roaring!" - they have been doing that for seven months now. Is the next rally already lurking around the corner?

    Read

    Commented by Stefan Feulner on September 23rd, 2022 | 10:10 CEST

    BYD, Kleos Space, Palantir - Market leaders in the clearance sale

    • Space
    • Electromobility
    • Technology

    In the wake of the major interest rate hike, the US Federal Reserve increased by 75 basis points, and the stock markets again went into a dive. After the statement by Chairman Jerome Powell, the Dow Jones lost more than 1,000 points over the day, and the Nasdaq technology index also ended the day with significant losses. That threatens a further test of the lows for the year. In the course of this, established market leaders from various sectors corrected and now offer attractive long-term entry opportunities at a reduced level.

    Read